Early findings from a national quality improvement (QI) program to address disparities in bladder cancer (BLCA) care.

A Ali Raza Khaki (Stanford Cancer Institute, Stanford, CA) F Fionna Sun (University of California, San Francisco, San Francisco, CA) P Patrick J. Hensley (Department of Urology, University of Kentucky Markey Cancer Center, Lexington, KY) M Mary Dunn (American Heart Association, Dallas, Texas, United States) R Rebecca Peebles (St. Jude Medical Center, Fullerton, CA) S Stephanie Chisolm (Bladder Cancer Advocacy Network, Bethesda, MD) K Karen Johnson (UNIVERSITY TENNESSEE, Memphis, Tennessee, United States) M Manish A. Vira (Northwell Health, Lake Success, NY) B Bradley Curtis Carthon (Winship Cancer Institute of Emory University, Atlanta, GA) A Allison Harvey (Rhizome, LLC, Washington, DC) C Christina Mangir (Rhizome, LLC, Washington, DC) C Caroline Offit (1Association of Cancer Care Centers, Rockville, United States) M Molly Kisiel (1Association of Cancer Care Centers, Rockville, United States) E Elana Plotkin (Association of Cancer Care Centers (ACCC), Rockville, MD) S Samuel L Washington (Department of Urology, University of California, San Francisco, San Francisco, CA) H Heather Honoré Goltz (University of Houston-Downtown, Houston, TX)

Abstract

697 Background: Rates of guideline-concordant treatment for BLCA remain <50%, driven by access and care delivery barriers. The Association of Cancer Care Centers (ACCC) designed a 6-month QI program to identify and implement site-specific strategies to support equitable care delivery at cancer programs. We aim to characterize findings from participating sites’ pre-implementation assessments as well as initial directions for QI. Methods: The ACCC QI program was conducted with cancer programs between November 2023 – November 2024, guided by an advisory committee, patient advocacy partners, and multidisciplinary faculty. Each program completed a pre-assessment to characterize organizational resources, catchment population demographics, patient volume, sentiment regarding organizational culture, practice patterns and identified barriers. Open-ended questions and those regarding sentiment used a 5-point Likert scale. During each in-person workshop, participants discussed barriers and prioritized interventions using an impact-feasibility matrix. Descriptive summary data are presented. Results: Three programs (one in California, North Carolina and Kentucky) were selected; one in an urban setting and two suburban; two NCI-designated and one Comprehensive Community Cancer program. Annual case volumes ranged from 103-1439, with 167-220 new diagnoses; >50% of cases were non-muscle invasive at each site and male-predominant (up to 30% female), with variable patient diversity (up to 50% Asian and 15% Black). Insurance coverage varied across programs: 52-80% Medicare, 17-29% Private, 0-3% uninsured. All programs agreed/strongly agreed leadership, staff and multidisciplinary team members were committed to improving equitable care, but only 1 program had processes to regularly assess disparities and 1 felt they had adequate training or culturally appropriate educational materials. Program-specific barriers to care included limitations around transportation support, limited care coordination, few community practitioners providing specialized care, and limited awareness of available resources. Based on impact and feasibility ratings, intervention targets included assessing and aligning care coordination preferences, mapping supportive care resources and addressing gaps, and tailoring educational materials to patient populations. Conclusions: Our study demonstrates a strong recognition by health systems of disparities affecting BLCA care, shows the feasibility of developing a QI program focused on addressing disparities in diverse practice settings and highlights the importance of systems-level support. Implementing mitigation strategies require program-specific understanding of barriers to provide equitable care. Health systems level strategies require a community-based approach to address barriers and deliver equitable care tailored to the needs of communities served.

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 697-697
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (16)

A

Ali Raza Khaki

Stanford Cancer Institute, Stanford, CA

F

Fionna Sun

University of California, San Francisco, San Francisco, CA

P

Patrick J. Hensley

Department of Urology, University of Kentucky Markey Cancer Center, Lexington, KY

M

Mary Dunn

American Heart Association, Dallas, Texas, United States

R

Rebecca Peebles

St. Jude Medical Center, Fullerton, CA

S

Stephanie Chisolm

Bladder Cancer Advocacy Network, Bethesda, MD

K

Karen Johnson

UNIVERSITY TENNESSEE, Memphis, Tennessee, United States

M

Manish A. Vira

Northwell Health, Lake Success, NY

B

Bradley Curtis Carthon

Winship Cancer Institute of Emory University, Atlanta, GA

A

Allison Harvey

Rhizome, LLC, Washington, DC

C

Christina Mangir

Rhizome, LLC, Washington, DC

C

Caroline Offit

1Association of Cancer Care Centers, Rockville, United States

M

Molly Kisiel

1Association of Cancer Care Centers, Rockville, United States

E

Elana Plotkin

Association of Cancer Care Centers (ACCC), Rockville, MD

S

Samuel L Washington

Department of Urology, University of California, San Francisco, San Francisco, CA

H

Heather Honoré Goltz

University of Houston-Downtown, Houston, TX